Navigation Links
Glycotex Finalizes Collaboration Agreement with Advanced Medical Solutions

ROCKVILLE, Md., Oct. 17 /PRNewswire/ -- Glycotex, Inc. today announced that it has finalized an agreement with U.K.-based Advanced Medical Solutions (AMS) to study the use of GLYC-101 with wound dressings manufactured by AMS.

Through this collaboration, Glycotex and AMS have agreed to an initial phase of testing of the use of GLYC-101 with AMS' wound dressings. Under the agreement, in the event that this first phase of testing gives rise to favorable results, or generates data that suggest further research may be warranted, Glycotex and AMS will have an opportunity to extend their collaboration for the purposes of continued research.

About GLYC-101

GLYC-101 is intended to stimulate and modulate the natural cascade of wound healing activities of several cell populations. The product candidate currently under development is a topical gel to be applied directly on the wound surface. The strategic priorities for GLYC-101 include wound healing following laser ablation, burn wounds, surgical wounds, venous ulcers and diabetic ulcers.

In May 2006, Glycotex completed a Phase II clinical trial of GLYC-101 in Australia, in which GLYC-101 produced a statistically significant rate of wound area reduction versus combined placebo and standard care in patients with chronic venous ulcers. The results provided proof-of concept and dose-ranging information for GLYC-101. In U.S. clinical trials, GLYC-101 is being assessed for safety and effectiveness on wound closure in patients undergoing carbon dioxide laser skin resurfacing.

About Advanced Medical Solutions

Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative and technologically advanced woundcare products.

In-house natural and synthetic polymer technology is used to provide advanced wound dressings based on the moist healing principle. AMS' resources ensure a unique position as a vertically integrated 'one stop shop' to provide all categories of moist wound healing products. AMS has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

The acquisition of 49.4 percent of Corpura BV in May 2008 strengthened AMS' position in hydrophilic polyurethane foam -- the largest and fastest growing segment of the advanced woundcare market.

AMS' technology in cyanoacrylate based tissue adhesives is used either for the closure of small cuts and trauma wounds through to large surgical incisions, or for protecting or sealing skin to prevent breakdown or infection.

AMS' products currently serve the majority of the key global markets sold either direct or through strategic partners or distributors.

Visit --

About Glycotex, Inc.

Glycotex, Inc. is a U.S. based development stage biopharmaceutical company focused on discovering and developing therapies intended to accelerate human wound healing and tissue repair across a wide range of human applications. It has licensed from Novogen Limited certain patent rights and know-how to use and exploit its technology in a wide range of wound healing applications. Glycotex, Inc. is an 81 percent owned subsidiary of Novogen Limited. For more information, visit

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates, costs and delays in the development and/or FDA approval, or the failure of our products to obtain such approval, uncertainties in clinical trial results, our inability to maintain or enter into, and the risks resulting from, our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, competitive factors, our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business, our inability to operate our business without infringing the patents and proprietary rights of others, general economic conditions, the failure of any products to gain market acceptance, our inability to obtain any additional required financing, technological changes, government regulation, changes in industry practice and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

SOURCE Glycotex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. HealthSouth Finalizes Acquisition of Rehabilitation Unit at Medical Center of Arlington
2. HealthSouth Finalizes Purchase of New Jersey Rehabilitation Hospital
3. HealthSouth Finalizes Sale of Corporate Campus to Daniel Corporation
4. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
5. Independence Blue Cross Finalizes New Multi-Year Agreements with Mercy Health System and St. Mary Medical Center
6. QUANTEL Finalizes the Acquisition of WaveLight Aesthetic GmbH
7. WuXi PharmaTech Expands Collaboration for Fully Integrated Services
8. Gene Network Sciences Announces Drug Development Collaboration with Biogen Idec
9. Nanobiotix and BiotechCorp Announce Initial Focus of Their Collaboration: P-O-C Diagnostics and Drug Delivery Systems for Tropical Diseases, Such as Malaria
10. Varian Medical Systems Signs Collaboration Agreement to Bring Advanced Radiotherapy Equipment to Indonesia
11. MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
Post Your Comments:
(Date:11/24/2015)... ALEXANDRIA, VA (PRWEB) , ... November 24, 2015 ... ... encourages people across the United States to support their local poison centers through ... been designated as #GivingTuesday: calls it “a day that inspires people to ...
(Date:11/24/2015)... Marne, MI (PRWEB) , ... November 24, 2015 , ... ... has released a series of recent video interviews with some of the staff members ... life at the residential treatment facility, as well as some of the things that ...
(Date:11/24/2015)... ... ... Aided by seed funding from the Ron Foley Foundation, researchers at Western ... how to detect and treat pancreatic cancer (PC). , WCHN researchers will focus ... (ncRNA), genetic material that is present in the blood of patients with PC. ...
(Date:11/24/2015)... ... November 24, 2015 , ... Abington Hospital – Jefferson ... of Quality® Bariatric Surgery Facility for treating individuals living with morbid or extreme ... services available to its members to help them make informed decisions about their ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Rodney E. Willey , has answered a ... Koala Center for Sleep Disorders, provides treatment for snoring and sleep apnea through ... a Koala Center for Sleep Disorders in the US, one of four in the Illinois ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , November 24, 2015 --> ... report "Spine Biologics Market by Product Type (Bone Graft, Bine ... Discectomy and Fusion, Posterior Lumbar Interbody Fusion), End User, and ... global market was valued at $1.90 Billion in 2014 and ... CAGR of 4.4% during the forecast period of 2015 to ...
(Date:11/24/2015)... LAUSANNE and BERN, Switzerland ... SA, the ARTORG Center for Biomedical Engineering Research of ... and the Division of Endocrinology, Diabetes and Clinical Nutrition ... announce the start of an exclusive collaboration to develop ... control algorithm for the personalised delivery of insulin for ...
(Date:11/24/2015)... st  Scientific Assembly and Annual Meeting of the Radiological Society ... Chicago on Nov-29 th through Dec-4 ...  Scientific Assembly and Annual Meeting of the Radiological Society of ... Chicago on Nov-29 th through Dec-4 th , ... present its revolutionary whole body CZT digital SPECT/CT solution at the ...
Breaking Medicine Technology: